RESUMEN
Cytomegalovirus (CMV) was first identified in the 1950s and noted to cause newborn disease in the 1960s. It is now known to be the most common cause of congenital infection in the world, leading to various central nervous system sequelae, the most common being hearing loss. Cytomegalovirus is a ubiquitous pathogen that affects nearly 30,000 infants annually in the United States, leading to 3,000-4,000 cases of hearing loss. Prevention through vaccination has proved unreliable, as has the use of immune globulin. Prevention through education has been shown to be the most effective method of minimizing infection. Antiviral therapy is effective at reducing the impact of infection on newborns. Continued global efforts will hopefully provide more solutions for this opportunistic infection.
Asunto(s)
Antivirales/normas , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/historia , Inmunoglobulinas Intravenosas/normas , Enfermería Neonatal/normas , Tamizaje Neonatal/normas , Guías de Práctica Clínica como Asunto/normas , Antivirales/uso terapéutico , Infecciones por Citomegalovirus/epidemiología , Femenino , Predicción , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Lactante , Recién Nacido , Masculino , Enfermería Neonatal/tendencias , Tamizaje Neonatal/tendencias , Estados Unidos/epidemiologíaRESUMEN
Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of autoimmune and systemic inflammatory diseases with both licensed and off-label indications. Recent studies indicated that IVIg-mediated immunomodulation and anti-inflammation are closely associated with the IgG sialylation, especially with IgG crystallizable fragment (Fc) sialylation. The sialic acid levels of the IgG molecules and Fc fragments in 12 IVIg preparations from six Chinese manufacturers were evaluated. The Fc fragments were derived from the papain digestion of IVIg, followed by affinity and size exclusion chromatography. The sialic acid levels in Fc fragments and IVIg preparations were determined by high-performance liquid chromatography with fluorescence detection, after the sialic acid residues were released from the proteins. The results showed that the sialic acid levels in Chinese IVIg preparations ranged from 0.875 (mol/mol IgG) to 1.085 (mol/mol IgG), and the sialic acid levels in Fc fragments were from 0.321 (mol/mol Fc) to 0.361 (mol/mol Fc). Furthermore, the sialic acid levels of IVIg preparations and Fc fragments from different Chinese manufactures were significantly different. These findings will contribute to an increased understanding of Chinese IVIg preparations and the relationship between the sialic acid levels in IVIg preparations and their clinical efficacy in future clinical studies.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Inmunoglobulinas Intravenosas/química , Ácido N-Acetilneuramínico/análisis , Humanos , Inmunoglobulinas Intravenosas/análisis , Inmunoglobulinas Intravenosas/normas , Modelos Lineales , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de FluorescenciaRESUMEN
Aggregates of human plasma-derived intravenous immunoglobulins (IVIGs) carries a risk of severe adverse events after nonspecific complement activation induced in humans administrated. Therefore, the anti-complementary activity (ACA) test is legally required in every batch of IVIGs in Japan. However, due to the intrinsic nature of this bioassay, there might be large differences in the results of ACA tests from laboratories, even when the same batch of IVIGs was measured. Our six laboratories evaluated whether there were such differences and argued for establishment of a reference material (RM) for standardization of the ACA test. Our results revealed inter-laboratory differences in ACA values, indicating a need to establish an RM. Therefore, after ACA values in candidate RMs were measured collaboratively, one RM was selected from two candidates and unit value-assigned. The RM in fact normalized the ACA test values for samples measured in parallel at almost all the laboratories, when the values were calculated relative to the assigned unit value of the RM. Thus, we established a first RM to standardize the ACA test in Japan, which enabled each laboratory to normalize ACA values constantly for IVIGs. This indicates that the establishment of an RM can contribute to quality control of IVIGs.
Asunto(s)
Activación de Complemento/efectos de los fármacos , Inactivadores del Complemento/farmacología , Inmunoglobulinas Intravenosas/farmacología , Animales , Bioensayo/métodos , Bioensayo/normas , Calibración , Inactivadores del Complemento/normas , Conducta Cooperativa , Cobayas , Humanos , Inmunoglobulinas Intravenosas/normas , Japón , Laboratorios/normas , Control de Calidad , Estándares de Referencia , Reproducibilidad de los Resultados , OvinosRESUMEN
Polyvalent immunoglobulin G (IgG) products obtained by fractionation of human plasma are used to treat a broad range of conditions, including immunodeficiency syndromes and autoimmune, inflammatory, and infectious diseases. Recent incidences of increased thromboembolic events (TEEs) associated with intravenous (IV) IgG (IVIG) led to recalls of some products and increased regulatory oversight of manufacturing processes in order to ensure that products are essentially free of procoagulant/thrombogenic plasma protein contaminants. Laboratory investigations have now identified activated factor XI (FXIa) as the likely causative agent of IVIG-related TEEs. Quantification of the thrombogenic potential is becoming a requirement made to fractionators (a) to validate the capacity of IVIG and subcutaneous IgG manufacturing processes to remove procoagulant contaminants and (b) to establish the safety of the final products. However, in the absence of a recommended test by the main regulatory authorities, several analytical approaches have been evaluated by fractionators, regulators, and university groups. This review focuses on the scientific rationale, merits, and applications of several analytical methods of quantifying the thrombogenic potential of IgG products and intermediates to meet the latest regulatory requirements.
Asunto(s)
Productos Biológicos/efectos adversos , Productos Biológicos/sangre , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/sangre , Tromboembolia/etiología , Animales , Productos Biológicos/normas , Factores de Coagulación Sanguínea/efectos adversos , Factores de Coagulación Sanguínea/aislamiento & purificación , Química Farmacéutica , Contaminación de Medicamentos/prevención & control , Factor XIa/efectos adversos , Factor XIa/aislamiento & purificación , Humanos , Inmunoglobulinas Intravenosas/efectos adversos , Inmunoglobulinas Intravenosas/normas , Factores Inmunológicos/efectos adversos , Factores Inmunológicos/sangre , Medición de Riesgo , Tromboembolia/sangre , Tromboembolia/inmunologíaRESUMEN
The level of anti-D antibodies in human immunoglobulin products for intravenous administration (IVIG) is controlled by the direct haemagglutination method prescribed by the European Pharmacopoeia (Ph. Eur.) that requires 2 control reference reagents. The World Health Organization (WHO) positive control International Reference Reagent (IRR; 02/228) with a nominal titre of 8 defines the highest acceptable titre, while the negative control preparation (02/226) has a nominal titre of <2. Working reference preparations (04/132 and 04/140) were subsequently established as Biological Reference Preparations (BRPs) for the Ph. Eur., and for distribution by the United States Food and Drug Administration (US FDA) and the National Institute for Biological Standards and Control (NIBSC). Due to diminishing stocks of these working reference preparations across the 3 institutions, a joint international study was organised to establish harmonised replacement batches. Sixteen laboratories contributed data to the study to evaluate positive and negative candidate replacement batches (13/148 and 12/300, respectively) against the WHO positive and negative control IRRs and the current working reference preparations (BRPs). The results show that the candidate reference preparations (13/148 and 12/300) are indistinguishable from the corresponding IRRs and current BRPs. The candidate preparations 13/148 and 12/300 were adopted by the Ph. Eur. Commission as Immunoglobulin (anti-D antibodies test) BRP batch 2 and Immunoglobulin (anti-D antibodies test negative control) BRP batch 2 with nominal haemagglutination titres of 8 and <2, respectively. The same materials were also adopted as NIBSC and US FDA reference preparations, thus ensuring full harmonisation.
Asunto(s)
Estándares de Referencia , Humanos , Inmunoglobulinas Intravenosas/normas , Inmunoglobulinas Intravenosas/farmacología , Inmunoglobulinas Intravenosas/análisis , Globulina Inmune rho(D) , Química Farmacéutica/normas , Química Farmacéutica/métodosAsunto(s)
Actitud Frente a la Salud , Inmunoglobulinas Intravenosas/uso terapéutico , Percepción/fisiología , Potencia de la Vacuna , Congresos como Asunto , Historia del Siglo XXI , Humanos , Inmunoglobulinas Intravenosas/normas , Síndromes de Inmunodeficiencia/epidemiología , Síndromes de Inmunodeficiencia/inmunología , Síndromes de Inmunodeficiencia/terapia , Sarampión/prevención & control , Poliomielitis/prevención & control , Enfermedades Raras , Características de la ResidenciaRESUMEN
BACKGROUND: Studies have demonstrated that traces of activated factor XI (FXIa) present in specific brands of intravenous immunoglobulin (IVIG) concentrates may pose a thrombogenic risk. AIM: To characterize procoagulant activity during fractionation and the elimination capacity of the Flebogamma(®) DIF (Grifols' IVIG) manufacturing process. METHODS: Flebogamma(®) DIF fractionation steps included cryoprecipitate supernatant (Cryo/S), Fraction (Fr) I supernatant, and Fr II + III suspension. Purification steps included ultrafiltrate I, acid treatment, and pasteurization. Samples were assessed for total protein, IgG, and procoagulant activation markers. RESULTS: Cryo/S showed no procoagulant activity for prekallikrein activator (PKA), kallikrein-like, and non-activated partial thromboplastin time (NaPTT) with normal (-PPP) or FXI-deficient (-FXI) platelet poor plasma. Thrombin generation test (TGT)-PPP and TGT-FXI were <83-148 and <53-197 nM thrombin, respectively. Shortened NaPTTs (100-296 s), high PKA (51-119 IU/mL), kallikrein-like activities (0.043-0.075 ΔAU/min), positive TGTs (98-298 nM), and FXIa (9.5-14.0 ng/mL) were detected in Fr II + III. After pasteurization, no residual evidence of any procoagulant activity marker was observed, including the final IVIG concentrate at 5% or 10% protein. Results were similar in Fr II + III from different IVIG manufacturing facilities. CONCLUSIONS: The Flebogamma(®) DIF production process is capable of eliminating procoagulant activity because of its purification steps.
Asunto(s)
Coagulantes/aislamiento & purificación , Contaminación de Medicamentos/prevención & control , Factor XIa/aislamiento & purificación , Inmunoglobulinas Intravenosas/aislamiento & purificación , Fraccionamiento Químico/métodos , Coagulantes/análisis , Factor XIa/análisis , Humanos , Inmunoglobulinas Intravenosas/análisis , Inmunoglobulinas Intravenosas/normas , Control de Calidad , Reproducibilidad de los ResultadosRESUMEN
Virus reduction by several steps in the manufacturing process for the intravenous immunoglobulin Vigam(®), has been investigated. The solvent/detergent step based on treatment with 0.3% tri-n-butyl phosphate and 1% polysorbate 80 at 37 °C, was confirmed to be effective for a range of enveloped viruses. Virus infectivity was undetectable i.e. >6 log inactivation within 30 min of the standard 6 h process. This was consistent over the range of conditions tested i.e. solvent/detergent and protein concentration, temperature and pH. The ion-exchange chromatography step in the process was also able to remove some viruses. Virus spiked followed by blank column runs confirmed the effectiveness of the sanitisation step for ensuring there was no virus cross contamination between column runs. The terminal low pH incubation step was also able to inactivate enveloped viruses, as well as some non-enveloped viruses. The combination of these three steps ensures a high margin of virus safety for this product.
Asunto(s)
Detergentes/farmacología , Inmunoglobulinas Intravenosas/química , Solventes/farmacología , Inactivación de Virus , Fraccionamiento Químico/métodos , Cromatografía por Intercambio Iónico/métodos , Relación Dosis-Respuesta a Droga , Contaminación de Medicamentos/prevención & control , Humanos , Concentración de Iones de Hidrógeno , Inmunoglobulinas Intravenosas/aislamiento & purificación , Inmunoglobulinas Intravenosas/normas , Límite de Detección , Temperatura , Carga Viral/efectos de los fármacos , Virus/efectos de los fármacos , Virus/aislamiento & purificaciónRESUMEN
INTRODUCTION: Dermatomyositis (DM) is an inflammatory myopathy characterized by distinct skin manifestations and muscle weakness. Intravenous immunoglobulin (IVIg) has been used off-label as adjuvant therapy in DM, but is not indicated for DM, due to lack of proven efficacy in a large randomized controlled trial. The objective of the ProDERM (Progress in DERMatomyositis) study was to evaluate the efficacy, safety and long-term tolerability of IVIg (Octagam 10%) in patients with DM in a randomized, placebo-controlled, double-blind, Phase III study. METHODS: Adult patients with active DM who were continuing standard therapy at a stable dose were eligible for this study. Patients were randomized 1:1 to receive either 2âg/kg of IVIg or placebo, administered every 4 weeks until week 16 (First Period). Patients were switched to the alternate treatment if they showed clinical deterioration in the First Period. After response assessment at week 16, all patients on placebo and those without deterioration on IVIg entered the open-label Extension Period, receiving 2âg/kg IVIg every 4 weeks for 24 weeks. RESULTS: The primary efficacy endpoint was the proportion of responders in the IVIg vs placebo arm at week 16, where response was defined per 2016 ACR/EULAR Myositis Response Criteria of at least minimal improvement [Total Improvement Score (TIS) ≥20] and without deterioration at 2 consecutive visits up to week 16. TIS consists of composite response criteria, combining weighted improvement in 6 core set measures (CSMs), Global Disease Activity (Physician and Patient), manual muscle testing-8 (MMT-8), Health Assessment Questionnaire, extra-muscular disease activity, and muscle enzymes. Secondary endpoints included the mean change in individual CSMs, time to improvement in TIS, time to confirmed deterioration in the First Period, and the overall proportion of patients with deteriorations. Adverse events, including infusion reactions and thromboembolic events, were recorded. CONCLUSIONS: The ProDERM study was the first to assess the long-term efficacy and safety of IVIg (Octagam 10%) in a placebo-controlled, blinded, randomized trial in DM. The study aimed to inform on the use of IVIg in the treatment of DM, and results are expected in Q3 2020. CLINICALTRIALSGOV IDENTIFIER: NCT02728752.
Asunto(s)
Dermatomiositis/tratamiento farmacológico , Inmunoglobulinas Intravenosas/normas , Adulto , Método Doble Ciego , Femenino , Humanos , Inmunoglobulinas Intravenosas/farmacología , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Persona de Mediana Edad , Placebos , Estudios Prospectivos , Resultado del TratamientoAsunto(s)
Inmunoglobulina G , Inmunoglobulinas Intravenosas , Humanos , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/uso terapéutico , Inmunoglobulinas Intravenosas/efectos adversos , Inmunoglobulinas Intravenosas/normas , Inmunoglobulinas Intravenosas/uso terapéutico , Infusiones Intravenosas , Infusiones Subcutáneas , Estados UnidosRESUMEN
Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.
Asunto(s)
Inmunoglobulinas Intravenosas/normas , Fraccionamiento Químico , Humanos , Inmunoglobulinas Intravenosas/aislamiento & purificación , Inmunoglobulinas Intravenosas/uso terapéutico , Garantía de la Calidad de Atención de Salud , Control de Calidad , Inactivación de VirusRESUMEN
A new human liquid intravenous immunoglobulin product, Flebogamma DIF, has been developed. This IgG is purified from human plasma by cold ethanol fractionation, PEG precipitation and ion exchange chromatography. The manufacturing process includes three different specific pathogen clearance (inactivation/removal) steps: pasteurization, solvent/detergent treatment and Planova nanofiltration with a pore size of 20 nm. This study evaluates the pathogen clearance capacity of seven steps in the production process for a wide range of viruses through spiking experiments: the three specific steps mentioned above and also four more production steps. Infectivity of samples was measured using a Tissue Culture Infectious Dose assay (log(10) TCID(50)) or Plaque Forming Units assay (log(10) PFU). Validation studies demonstrated that each specific step cleared more than 4 log(10) for all viruses assayed. An overall viral clearance between > or =13.33 log(10) and > or =25.21 log(10), was achieved depending on the virus and the number of steps studied for each virus. It can be concluded that Flebogamma DIF has a very high viral safety profile.
Asunto(s)
Contaminación de Medicamentos/prevención & control , Inmunoglobulinas Intravenosas/aislamiento & purificación , Inmunoglobulinas Intravenosas/normas , Inactivación de Virus , Fraccionamiento Químico , Cromatografía por Intercambio Iónico , Detergentes/química , Humanos , Inmunoglobulinas Intravenosas/química , Plasma/química , Plasma/virología , Polietilenglicoles/química , Solventes/química , Esterilización/métodos , Ultrafiltración/instrumentación , Ultrafiltración/métodos , Ensayo de Placa ViralRESUMEN
OBJECTIVE: To investigate the usefulness of procalcitonin (PCT) as predictive factors of intravenous immunoglobulin (IVIG)-resistant Kawasaki disease patients. METHODS: We retrospectively analyzed the laboratory data from 215 children with Kawasaki disease treated with IVIG from 2014 to 2019. We analyzed the clinical and laboratory parameters just before the IVIG including serum levels of PCT with respect to the IVIG response. RESULTS: Eventually, 127 patients were analyzed. The median age was 2.4 years. IVIG was effective in 108 children (responders) and was ineffective in 19 (non-responders). Serum PCT concentration was higher in non-responders than those of responders (P < 0.001). Multivariate logistic regression analyses indicated that higher PCT concentration (odds ratio 1.34, 95% confidence interval 1.10-1.64) were associated with IVIG resistance. Analyses of the receiver operating characteristic curve showed that the cutoff value of PCT 2.18 ng/mL had 46.4% of sensitivity and 93.9% of specificity. Receiver operating characteristic analysis yielded an area under the curve of 0.82 (0.72-0.92) to predict IVIG resistance. CONCLUSIONS: Serum PCT value can be an excellent biomarker for predicting unresponsiveness to IVIG with a good discriminatory ability as well as the existing prediction scores.
Asunto(s)
Inmunoglobulinas Intravenosas/uso terapéutico , Síndrome Mucocutáneo Linfonodular/terapia , Polipéptido alfa Relacionado con Calcitonina/sangre , Biomarcadores/sangre , Niño , Preescolar , Femenino , Humanos , Inmunoglobulinas Intravenosas/normas , Lactante , Modelos Logísticos , Masculino , Síndrome Mucocutáneo Linfonodular/diagnóstico , Análisis Multivariante , Oportunidad Relativa , Valor Predictivo de las Pruebas , Polipéptido alfa Relacionado con Calcitonina/normas , Estudios Retrospectivos , Insuficiencia del TratamientoRESUMEN
Flebogamma 5% dual inactivation and filtration (DIF), a new 5% liquid intravenous immunoglobulin with a stability of 2 years when stored at temperatures between 2 and 30 degrees C, has been developed. This new product is the result of the accumulated experience provided by Flebogamma, with more than 30 million grams administered since 1992 in Europe and the United States, and the implementation of the latest technology to improve Flebogamma even more by increasing its viral safety margin further. In addition to the specific inactivation stage for Flebogamma 5% (pasteurization), the new process includes a solvent-detergent treatment and nanofiltration through a Planova filter down to 20 nm. The preparation presents a mean purity of 99.6 +/- 0.2% with a correct chromatographic profile. Percentage values of immunoglobulin (Ig)G subclasses are equivalent to the physiological values of normal serum. The content in IgA as well as other possible impurities is very low, and the product presents a mean result of 109 +/- 5% in the Fc fragment functionality assay, demonstrating the integrity of the IgG molecule. The functionality is also reflected in neutralization tests carried out against poliomyelitis, diphtheria, measles and vaccinia which, apart from the antibody titres determined by enzyme-linked immunosorbent assay, guarantees that antibodies are capable of reacting against these pathogens. Regarding safety, the combination of multiple methods with capacity to inactivate or remove biological agents which include chemical inactivation, heat inactivation, nanofiltration and precipitations, with very different mechanisms of action, provides Flebogamma 5% DIF very wide margins of safety regarding to potential pathogens.
Asunto(s)
Inmunoglobulinas Intravenosas/normas , Contaminación de Medicamentos/prevención & control , Descubrimiento de Drogas/métodos , Estabilidad de Medicamentos , Humanos , Inmunoelectroforesis/métodos , Inmunoglobulina G/análisis , Inmunoglobulinas Intravenosas/química , Inmunoglobulinas Intravenosas/inmunología , Peso Molecular , Nanotecnología/métodos , Administración de la Seguridad/métodos , Ultrafiltración/métodos , Inactivación de Virus , Virus/aislamiento & purificaciónAsunto(s)
Inmunoglobulinas Intravenosas/administración & dosificación , Síndromes de Inmunodeficiencia/terapia , Vías de Administración de Medicamentos , Humanos , Inmunoglobulinas Intravenosas/economía , Inmunoglobulinas Intravenosas/normas , Síndromes de Inmunodeficiencia/epidemiología , Síndromes de Inmunodeficiencia/inmunología , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/normasRESUMEN
Polyvalent human normal immunoglobulins for intravenous use (IVIg), indicated for rare and often severe diseases, are complex plasma-derived protein preparations. A quality by design approach has been used to develop the Laboratoire Français du Fractionnement et des Biotechnologies new-generation IVIg, targeting a high level of purity to generate an enhanced safety profile while maintaining a high level of efficacy. A modular approach of quality by design was implemented consisting of five consecutive steps to cover all the stages from the product design to the final product control strategy.A well-defined target product profile was translated into 27 product quality attributes that formed the basis of the process design. In parallel, a product risk analysis was conducted and identified 19 critical quality attributes among the product quality attributes. Process risk analysis was carried out to establish the links between process parameters and critical quality attributes. Twelve critical steps were identified, and for each of these steps a risk mitigation plan was established.Among the different process risk mitigation exercises, five process robustness studies were conducted at qualified small scale with a design of experiment approach. For each process step, critical process parameters were identified and, for each critical process parameter, proven acceptable ranges were established. The quality risk management and risk mitigation outputs, including verification of proven acceptable ranges, were used to design the process verification exercise at industrial scale.Finally, the control strategy was established using a mix, or hybrid, of the traditional approach plus elements of the quality by design enhanced approach, as illustrated, to more robustly assign material and process controls and in order to securely meet product specifications.The advantages of this quality by design approach were improved process knowledge for industrial design and process validation and a clear justification of the process and product specifications as a basis for control strategy and future comparability exercises.
Asunto(s)
Inmunoglobulinas Intravenosas/normas , Tecnología Farmacéutica/normas , Administración Intravenosa , Composición de Medicamentos , Contaminación de Medicamentos , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Inmunoglobulinas Intravenosas/química , Seguridad del Paciente , Control de Calidad , Gestión de Riesgos , Tecnología Farmacéutica/métodos , Flujo de TrabajoRESUMEN
Eight different batches of intravenous immunoglobulin from 3 different manufacturers were tested for neutralizing activities against all currently known streptococcal superantigens. Statistically significant variation among different intravenous immunoglobulin preparations (P<.0001) and between individual streptococcal superantigens (P<.0001) was observed. These results might be helpful for optimizing the type and dose of intravenous immunoglobulin used in adjunctive therapy for severe invasive streptococcal disease.
Asunto(s)
Antígenos Bacterianos/inmunología , Inmunoglobulinas Intravenosas/normas , Choque Séptico/tratamiento farmacológico , Infecciones Estreptocócicas/tratamiento farmacológico , Streptococcus/inmunología , Superantígenos/inmunología , Quimioterapia Adyuvante , Humanos , Inmunoglobulinas Intravenosas/inmunología , Inmunoglobulinas Intravenosas/uso terapéutico , Pruebas de NeutralizaciónRESUMEN
The use of immune globulin intravenous (IGIV) as replacement therapy in immunodeficiency disease and as anti-inflammatory or immunomodulatory therapy in a variety of autoimmune and inflammatory diseases has expanded dramatically over the last decade. With this expansion, new challenges and concerns have emerged. As well, new products have been introduced while others have been discontinued. This evolution poses the important issue of product selection, choosing the "right" product for an individual patient. As the manufacturing process, virus reduction methods, and final formulation and composition differ widely among these products, it is intuitive that clinical outcomes, including both safety and efficacy, could also differ. This review examines such differences among currently available products in the United States and their potential to affect clinical outcomes.
Asunto(s)
Inmunoglobulinas Intravenosas/normas , Inmunoglobulinas Intravenosas/uso terapéutico , Química Farmacéutica , Humanos , Inmunoglobulinas Intravenosas/efectos adversos , Resultado del TratamientoRESUMEN
Is the process the product? Immune globulin intravenous (IGIV) is not manufactured, but is purified (fractionated) from human plasma. Machines can only damage what Mother Nature makes; they cannot improve it. Therefore, fractionators of biologic molecules must strive to ensure what is taken from a human body is exactly the same when it is returned to the human body for optimal tolerability and safety. The processes of purification have the potential to adversely affect the product. Four primary purification processes exist for commercial IGIV. The Cohn-Oncley process is 1940s technology, which has been modified through the decades, but the basic process remains unchanged. The Kistler-Nitschmann process was developed in the 1950s by the Central Laboratory of the Swiss Red Cross (ZLB, today known as ZLB-Behring, a subsidiary of CSL Limited). Various attempts have been made to utilize chromatography as the sole separation technology without much success. Most recently, Bayer HealthCare (Talecris Biotherapeutics acquired the contributed assets of the worldwide plasma business of Bayer Biological Products and became operational April 1, 2005; all plasma-based products, including Gamunex, Prolastin, the hyperimmune line (Fraction II), Plasbumin (Bayer Albumin), Koate DVI, and Thrombate III were included) introduced a new product into the United States and Canada that utilizes caprylate and chromatography for high purity, better yields, and integration of safety and efficacy. This is the first new IGIV purification technology in over 20 years.